"Mom would not say "C" because it would have power over her."...

"Mom would not say "C" because it would have power over her."

Susan Sontag

My friends,

This week Tiresias has several interesting observations to report but will limit himself to two and be very brief about it. First, and very briefly, he would like to mention the pleasing turnover and the accumulation of Optiscan shares leaving the weak hands passing to strong, setting a very secure lower limit for the price. Tiresias need say no more about this as he is sure his friends understand his meaning.

Of much greater interest and long-term implication and significance for Optiscan shareholders is a scientific paper just published which came to Tiresias’s notice. Titled, "Transcriptomic Biomarkers Signatures for Discriminationof Oral Cancer Surgical Margins”, by Simon A. Fox, Michael Vacherand Camile S. Farah. Yes Camile S. Farah is the managing director/CEO of Optiscan, and the chief author and the designer of this study. This is a highly technical cutting-edge paper on histopathological diagnostic techniques in detection of oral cancer and detection of minimal residual disease at surgical margins and precancerous lesions distal to any lesions. It uses RNA profiles and utilising NB I(Narrow Band Imaging) nasendoscopy to directly visualise in situ cancer in the oral cavity. NBI uses a non-magnifying Olympus instrument which enhances the visualisation margin detection distal pre-cancer and cancer tumour. Before my friends panic, no this is not competition to Optiscan’s Confocal Laser Endomiscroscope, this merely points the way for Optiscan’s CLE and how to do this properly. The NBI is not a microscope, it’s just an endoscope, and cannot visualise at the 1000X magnification that the OIL instrument does. Clearly this study, had it used Optiscan CLE would be a landmark in cancer diagnosis and research. If old blind Tiresias can see this, he is certain that Professor Farah would have seen this a long time ago and would have wanted to be involved with Opti scan technology. How could he not be? Tiresias sees it all very clearly now; utilising these, and of courses many, many more in the pipeline, genomic cancer biomarkers, in conjunction with Optiscan real-time in vivo digital confocal laser endomicroscopy, applied to virtually all cancers and precancers, and not just oral tumours, is a game changer in diagnosis and surgical treatment all cancers of all bodily tissues. Enjoy the ride my friends.